I first came across Chembio when researching Alere - Chembio had licensed their technology to Alere but that finished in 2014.
"Through this grant, it is the goal of the Paul G. Allen Ebola Program to develop a simple, cost-effective, point-of-care diagnostic capable of testing for multiple diseases simultaneously"
Multiplexing and low cost production - Anteo could add value here IMO
Anteo's last quarterly had a fair amount of content on the POC work in lateral flow etc
Still waiting to find out who the below POC company is??
"In another instance we undertook paid research with another customer who is developing a novel point of care assay. We have managed to successfully solve a problem they had been working on for two years in 3 weeks."
Must be close to hearing AGM date?
Anyone know?
ADO Price at posting:
9.9¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)